News

Merck chief quits as further material on Vioxx emerges

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7500.1101-a (Published 12 May 2005) Cite this as: BMJ 2005;330:1101
  1. Ray Moynihan
  1. Sydney

    The chief executive officer and chairman of Merck, Raymond Gilmartin, resigned unexpectedly last week, the same day a damning US Congress report on the company was released.

    Even though Mr Gilmartin stepped down hurriedly a year ahead of schedule, Merck's official position is that the resignation was not connected to the growing global controversy over its anti-arthritis drug rofecoxib (Vioxx), which was withdrawn from the market late last year, after studies produced evidence …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe